Orchid Pharma Limited — PPTs, 26-05-2025: Investor Presentation

1. Financial Highlights:

Orchid Pharma reported sales of ₹922 Cr for FY-25, up 13% YoY, supported by steady business growth. Other income increased 7% to ₹32 Cr. Cost of goods sold rose 12%, with gross margins steady at around 41%. Employee expenses jumped 23%, and other expenses were up 8%. EBITDA grew 11% to ₹156 Cr, sustaining a 17% margin. Profit before tax rose 15% to ₹106 Cr, while profit after tax increased 12% to ₹95 Cr. Overall, EBITDA and PAT margins held stable at approximately 17% and 11%.

2. Strategic Initiatives & Growth Drivers:

The company is focused on capacity expansion alongside disciplined cost management. Although capex details were not disclosed, stable margins amid rising costs indicate operational efficiency gains. Growth is supported by new product launches and scaling up existing operations.

3. Business Developments:

No new acquisitions or partnerships were noted. The emphasis remains on enhancing current product portfolios and growing through organic initiatives.

4. Market Position & Competitive Advantage:

Orchid Pharma sustains a steady market position with consistent margins and rising profitability. Advantage comes from scale efficiencies and effective cost controls, helping offset inflationary pressures. The company benefits from a well-established brand and diverse product mix.

5. Investor Implications:

The strong revenue and profit growth combined with margin stability suggests positive growth potential. Investors should monitor the company’s execution on operational efficiencies and market expansion to ensure continued momentum.